---
title: "ABPRO HOLDINGS INC C/WTS 12/11/2029 (TO PUR COM) | 10-Q: FY2025 Q1 EPS: USD -0.08"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/240451225.md"
datetime: "2025-05-15T20:51:33.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/240451225.md)
  - [en](https://longbridge.com/en/news/240451225.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/240451225.md)
---

# ABPRO HOLDINGS INC C/WTS 12/11/2029 (TO PUR COM) | 10-Q: FY2025 Q1 EPS: USD -0.08

EPS: As of FY2025 Q1, the actual value is USD -0.08.

EBIT: As of FY2025 Q1, the actual value is USD -2.958 M.

### Segment Revenue

-   The company did not generate revenue during the three months ended March 31, 2025 and 2024.

### Operational Metrics

-   **Net Income (Loss)**: The company reported a net loss of - $3,887 for the three months ended March 31, 2025, compared to a net income of $636 for the same period in 2024.
-   **Research and Development Expenses**: Decreased by $0.7 million for the three months ended March 31, 2025, primarily due to the decrease in personnel being on furlough since October 2024.
-   **General and Administrative Expenses**: Increased by $0.8 million for the three months ended March 31, 2025, primarily due to an increase in costs of operating as a public company.

### Cash Flow

-   **Net Cash Used in Operating Activities**: - $1,719 for the three months ended March 31, 2025, compared to - $2,848 for the same period in 2024.
-   **Net Cash Provided by Financing Activities**: $132 for the three months ended March 31, 2025, compared to $2,345 for the same period in 2024.

### Unique Metrics

-   **Weighted Average Shares Outstanding**: Basic shares outstanding were 50,922,432 for the three months ended March 31, 2025, compared to 19,181,066 for the same period in 2024.

### Future Outlook and Strategy

-   **Core Business Focus**: The company plans to initiate clinical trials for ABP-102 and ABP-201 in 2026, focusing on HER2+ solid tumors and wet age-related macular degeneration (Wet AMD).
-   **Non-Core Business**: The company intends to monitor the market value of its listed securities and may consider available options to regain compliance with Nasdaq listing requirements.
-   **Priority**: The company expects to incur operating losses in the foreseeable future and plans to continue fundraising and seek alternate revenues from collaboration and license agreements.

### Related Stocks

- [ABPWW.US](https://longbridge.com/en/quote/ABPWW.US.md)

## Related News & Research

- [Micron or SK hynix: One AI Chip Stock Is a Bargain, the Other Too Expensive](https://longbridge.com/en/news/295285687.md)
- ['Playing With Fire': Investor Sounds the Alarm on Nvidia Stock](https://longbridge.com/en/news/295283156.md)
- [Trade Desk Blames Weak Consumer Spending, Tariffs and Oil Prices for Slowing Growth](https://longbridge.com/en/news/295227421.md)
- [Satya Nadella Said Microsoft's Own AI Chips Are Driving Up to 40% Efficiency Gains. Here's Why That Matters for Investors](https://longbridge.com/en/news/295257073.md)
- [Why Take-Two Interactive's Shares are Taking a Hit Amid Q1 Earnings](https://longbridge.com/en/news/295233021.md)